Supernus Pharmaceuticals, Inc.
SUPN
Hisse Senetlerindeki Sıralama
#5898
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Hisse Fiyatı
$37.86
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$2.20B
Değişim (1 gün)
-4.32%
Değişim (1 yıl)
-23.08%
Ülke
US
Ticaret Supernus Pharmaceuticals, Inc. (SUPN)
Kategori
Healthcare
Piyasa Değeri Supernus Pharmaceuticals, Inc.(SUPN)
Piyasa Değeri: $2.20B
October 2026 itibarıyla Supernus Pharmaceuticals, Inc. şirketinin piyasa değeri $2.20B. Bu, verilerimize göre Supernus Pharmaceuticals, Inc. şirketini dünyanın en değerli 5898th. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
Supernus Pharmaceuticals, Inc. piyasa değeri geçmişi (2018 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında SUPN
